Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2022 Jun 2

PMID 35654413

Authors

Alexandra Bukowski

Cathrine Hoyo

Michael G Hudgens

Wendy R Brewster

Fidel Valea

Rex C Bentley

Adriana C Vidal

Rachel L Maguire

John W Schmitt

Susan K Murphy

Kari E North

Jennifer S Smith

Affiliations

Soon will be listed here.

Abstract

Background: High-risk human papillomavirus (hrHPV) testing is utilized in primary cervical cancer screening, generally along with cytology, to triage abnormalities to colposcopy. Most screening-based hrHPV testing involves pooled detection of any hrHPV or of HPV16/18. Cervical neoplasia progression risks based on extended hrHPV genotyping-particularly non-16/18 hrHPV types-are not well characterized. HPV genotype-specific incidence of high-grade cervical intraepithelial neoplasia or more severe (CIN2+) following an abnormal screening result was examined.

Methods: We assessed a US-based prospective, multiracial, clinical cohort of 343 colposcopy patients with normal histology (n = 226) or CIN1 (n = 117). Baseline cervical samples underwent HPV DNA genotyping, and participants were followed up to 5 years. Genotype-specific CIN2+ incidence rates (IR) were estimated with accelerated failure time models. Five-year CIN2+ risks were estimated nonparametrically for hierarchical hrHPV risk groups (HPV16; else HPV18/45; else HPV31/33/35/52/58; else HPV39/51/56/59/68).

Results: At enrollment, median participant age was 30.1 years; most (63%) were hrHPV-positive. Over follow-up, 24 participants progressed to CIN2+ (7.0%). CIN2+ IR among hrHPV-positive participants was 3.4/1,000 person-months. CIN2+ IRs were highest for HPV16 (8.3), HPV33 (7.8), and HPV58 (4.9). Five-year CIN2+ risk was higher for HPV16 (0.34) compared with HPV18/45 (0.12), HPV31/33/35/52/58 (0.12), and HPV39/51/56/59/68 (0.16) (P = 0.05).

Conclusions: Non-16/18 hrHPV types are associated with differential CIN2+ progression rates. HPV16, 33, and 58 exhibited the highest rates over 5 years. HPV risk groups warrant further investigation in diverse US populations.

Impact: These novel data assessing extended HPV genotyping in a diverse clinical cohort can inform future directions to improve screening practices in the general population.

Citing Articles

HPV specificity and multiple infections and association with cervical cytology in Chongqing, China: a cross-sectional study.

Luo Q, Zhang H, Zeng X, Han N, Ma Z, Luo H BMC Infect Dis. 2024; 24(1):804.

PMID: 39123121 PMC: 11313099. DOI: 10.1186/s12879-024-09693-3.

Emerging trends and hotspots in cervical intraepithelial neoplasia research from 2013 to 2023: A bibliometric analysis.

Wang L, Sun B, Xu J, Cao D, Chen Y, Xu Y Heliyon. 2024; 10(11):e32114.

PMID: 38882369 PMC: 11177135. DOI: 10.1016/j.heliyon.2024.e32114.

Epigenome-wide methylation and progression to high-grade cervical intraepithelial neoplasia (CIN2+): a prospective cohort study in the United States.

Bukowski A, Hoyo C, Vielot N, Graff M, Kosorok M, Brewster W BMC Cancer. 2023; 23(1):1072.

PMID: 37932662 PMC: 10629205. DOI: 10.1186/s12885-023-11518-6.

Impact of cervical screening by human papillomavirus genotype: Population-based estimations.

Wang J, Elfstrom K, Lagheden C, Eklund C, Sundstrom K, Sparen P PLoS Med. 2023; 20(10):e1004304.

PMID: 37889928 PMC: 10637721. DOI: 10.1371/journal.pmed.1004304.

References

Olusola P, Banerjee H, Philley J, Dasgupta S . Human Papilloma Virus-Associated Cervical Cancer and Health Disparities. Cells. 2019; 8(6). PMC: 6628030. DOI: 10.3390/cells8060622. View

Niccolai L, Russ C, Julian P, Hariri S, Sinard J, Meek J . Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty. Cancer. 2013; 119(16):3052-8. DOI: 10.1002/cncr.28038. View

Spinillo A, Dal Bello B, Gardella B, Roccio M, Dacco M, Silini E . Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Gynecol Oncol. 2009; 113(1):115-9. DOI: 10.1016/j.ygyno.2008.12.037. View

Egemen D, Cheung L, Chen X, Demarco M, Perkins R, Kinney W . Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis. 2020; 24(2):132-143. PMC: 7147417. DOI: 10.1097/LGT.0000000000000529. View

Vidal A, Smith J, Valea F, Bentley R, Gradison M, Yarnall K . HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. Cancer Causes Control. 2014; 25(8):1055-62. PMC: 4082644. DOI: 10.1007/s10552-014-0406-2. View

Bonde J, Bottari F, Parvu V, Pedersen H, Yanson K, Iacobone A . Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort. Int J Cancer. 2019; 145(4):1033-1041. PMC: 6617734. DOI: 10.1002/ijc.32291. View

Trottier H, Mahmud S, Costa M, Sobrinho J, Duarte-Franco E, Rohan T . Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006; 15(7):1274-80. DOI: 10.1158/1055-9965.EPI-06-0129. View

Pista A, Oliveira A, Verdasca N, Ribeiro F . Single and multiple human papillomavirus infections in cervical abnormalities in Portuguese women. Clin Microbiol Infect. 2010; 17(6):941-6. DOI: 10.1111/j.1469-0691.2010.03387.x. View

Yang D, Soulos P, Davis B, Gross C, Yu J . Impact of Widespread Cervical Cancer Screening: Number of Cancers Prevented and Changes in Race-specific Incidence. Am J Clin Oncol. 2016; 41(3):289-294. PMC: 4958036. DOI: 10.1097/COC.0000000000000264. View

10.

Bonde J, Sandri M, Gary D, Andrews J . Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review. J Low Genit Tract Dis. 2019; 24(1):1-13. PMC: 6924950. DOI: 10.1097/LGT.0000000000000494. View

11.

SOOST H, LANGE H, Lehmacher W . The validation of cervical cytology. Sensitivity, specificity and predictive values. Acta Cytol. 1991; 35(1):8-14. View

12.

Stoler M, Wright Jr T, Parvu V, Yanson K, Cooper C, Andrews J . Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology. Gynecol Oncol. 2019; 153(1):26-33. DOI: 10.1016/j.ygyno.2018.12.024. View

13.

Yoo W, Kim S, Huh W, Dilley S, Coughlin S, Partridge E . Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One. 2017; 12(2):e0172548. PMC: 5325259. DOI: 10.1371/journal.pone.0172548. View

14.

Mayrand M, Duarte-Franco E, Rodrigues I, Walter S, Hanley J, Ferenczy A . Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357(16):1579-88. DOI: 10.1056/NEJMoa071430. View

15.

Saadeh K, Park I, Gargano J, Whitney E, Querec T, Hurley L . Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States. Vaccine. 2019; 38(1):39-45. DOI: 10.1016/j.vaccine.2019.09.103. View

16.

Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett T, Cheung L, Chen X . A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020; 22:100293. PMC: 7264956. DOI: 10.1016/j.eclinm.2020.100293. View

17.

Adcock R, Cuzick J, Hunt W, McDonald R, Wheeler C . Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia. Cancer Epidemiol Biomarkers Prev. 2019; 28(11):1816-1824. PMC: 8394698. DOI: 10.1158/1055-9965.EPI-19-0239. View

18.

Patel S, Mugo N, Cohen C, Ting J, Nguti R, Kwatampora J . Multiple human papillomavirus infections and HIV seropositivity as risk factors for abnormal cervical cytology among female sex workers in Nairobi. Int J STD AIDS. 2013; 24(3):221-5. DOI: 10.1177/0956462412472446. View

19.

Lindsey J, Ryan L . Tutorial in biostatistics methods for interval-censored data. Stat Med. 1998; 17(2):219-38. DOI: 10.1002/(sici)1097-0258(19980130)17:2<219::aid-sim735>3.0.co;2-o. View

20.

Tsui J, Llanos A, Doose M, Rotter D, Stroup A . Determinants of Abnormal Cervical Cancer Screening Follow-Up And Invasive Cervical Cancer Among Uninsured and Underinsured Women in New Jersey. J Health Care Poor Underserved. 2019; 30(2):680-701. PMC: 6612267. DOI: 10.1353/hpu.2019.0050. View